BCL2 and ovarian carcinoma: The costunolide contained in crude drug number 118 was reported to inhibit cell viability of multidrug-resistant human ovarian cancer OAW42-A cells by activating apoptotic and autophagic pathways via the decreased expression of B-cell lymphoma 2 (Bcl-2) [43].